Gyre Therapeutics (Gyre Therapeutics) ROCE % : 22.74% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gyre Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was 22.74%.

Gyre Therapeutics ROCE % Historical Data

The historical data trend for Gyre Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics ROCE % Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

39.87

12.52

22.74

Gyre Therapeutics Semi-Annual Data
	Dec21	Dec22	Dec23
ROCE %	39.87	12.52	22.74

Gyre Therapeutics ROCE % Calculation

Gyre Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	19.213	/	( ( (84.753 - 12.242)	+	(116.539 - 20.047) )	/ 2 )
	=	19.213	/	( (72.511	+	96.492)	/ 2 )
	=	19.213	/	84.5015
	=	22.74 %

Gyre Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	19.213	/	( ( (84.753 - 12.242)	+	(116.539 - 20.047) )	/ 2 )
	=	19.213	/	( ( 72.511	+	96.492 )	/ 2 )
	=	19.213	/	84.5015
	=	22.74 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

Gyre Therapeutics (NAS:GYRE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gyre Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023